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ABSTRACT
5-fluorouracil (5FU) is an effective anti-cancer drug,
yet its mechanism of action remains unclear. Here,
we examine the effect of 5FU on pre-mRNA splicing
in vivo. Using RT–PCR, we show that the splicing
of a number of pre-mRNAs is inhibited in HeLa
cells that have been exposed to a low dose of 5FU.
It appears that this inhibitory effect is not due to
its incorporation into pre-mRNA, because partially
or fully 5FU-substituted pre-mRNA, when injected
into Xenopus oocytes, is spliced just as well as is
the unsubstituted pre-mRNA. Detailed analyses of
5FU-treated cells indicate that 5FU is incorporated
into U2 snRNA at important naturally occurring
pseudouridylation sites. Remarkably, 5FU incor-
poration effectively blocks the formation of impor-
tant pseudouridines in U2 snRNA, as only a trace of
pseudouridine is detected when cells are exposed to
a low dose of 5FU for 5 days. Injection of the hypo-
pseudouridylated HeLa U2 snRNA into U2-depleted
Xenopus oocytes fails to reconstitute pre-mRNA
splicing, whereas control U2 isolated from untreated
or uracil-treated HeLa cells completely reconstitutes
the splicing. Our results demonstrate for the first
time that 5FU incorporates into a spliceosomal
snRNA at natural pseudouridylation sites in vivo,
thereby inhibiting snRNA pseudouridylation and
splicing. This mechanism may contribute substan-
tially to 5FU-mediated cell death.
INTRODUCTION
5-ﬂuorouracil (5FU), as a potent anti-cancer drug, has been
widely used since its discovery in the 1950s (1). However,
despite decades of intense study, the mechanism of action
of this drug remains unclear (2–4). It has been hypothesized,
and in some cases demonstrated, that 5FU directly affects
DNA metabolism (2,4). For instance, it has been shown
that 5FU, when converted into 5-ﬂuorodeoxyuridine
monophosphate (5FdUMP) in the cell, can tightly bind to
thymidylate synthase, an enzyme required for the conversion
of deoxyuridine monophosphate (dUMP) to deoxythymidine
monophosphate (dTMP), thereby inhibiting the synthesis of
dTMP and its downstream product dTTP and consequently
affecting DNA synthesis. As a consequence of thymidylate
synthase inactivation, dUMP accumulates, resulting in ele-
vated synthesis of its downstream product dUTP. The incorp-
oration of dUTP into DNA subsequently leads to DNA
damage. Puzzlingly, however, when 5FU-exposed cells are
treated with thymidine, which can be converted to dTMP
through the action of thymidine kinase (a pathway that is
independent of the thymidylate synthase pathway), 5FU-
mediated cytotoxic and apoptotic effects remain, suggesting
that DNA metabolism may not be a primary target of
5FU (5–8).
Given that 5FU can be readily converted into 5-
ﬂuorouridine triphosphate (5FUTP), a ribonucleotide analog
that can be incorporated into RNAs, it has been proposed
that 5FU may directly affect RNA metabolism (2–7). In this
regard, past research has focused largely on rRNA synthesis
(9–17). When included in culture media, 5FU is readily incor-
porated into the long single rRNA that is a precursor to 18S,
5.8S and 28S rRNAs, thus posing the question of whether
5FU incorporation directly affects pre-rRNA processing.
However, experimental results accumulated thus far are
inconclusive. For instance, some experiments suggested that
the incorporation of 5FU into pre-rRNA might inhibit
rRNA processing at early steps that lead to the production
of mature 18S rRNA (13,18–20). In contrast, Jacob and col-
leagues reported that 5FU-incorporated pre-rRNA, when
assayed in a cell-free system, was efﬁciently and accurately
processed at a primary cleavage site (no inhibition was
detected), although extracts prepared from 5FU-treated cells
exhibited a defect in rRNA processing at this site (3,10).
Recently, the Butler group observed that yeast strains hete-
rozygous for deletions of genes required for pre-rRNA pro-
cessing are more sensitive to 5FU compared with all other
heterozygous strains (17). They further detected an accumu-
lation of polyadenylated rRNAs in yeast strains that are
defective in the nuclear exosome component Rrp6p, an
exonuclease involved in rRNA processing and nuclear RNA
degradation, thus demonstrating and verifying the inhibitory
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unclear, however, whether the effect is a direct consequence
of 5FU incorporation into pre-rRNA.
The effect of 5FU on pre-mRNA splicing has also been
studied (2,4). However, the work presented over the years
has been largely fragmentary and inconclusive. Only a limi-
ted number of genes have been analyzed in 5FU-treated cells.
Among them, DHFR (dihydrofolate reductase) is perhaps
the most extensively studied. The levels of DHFR pre-
mRNA and mature mRNA increase in cultured cells upon
5FU treatment (14,15). Although the increase in mRNA is
open to interpretation, the fact that the level of DHFR pre-
mRNA is elevated in 5FU-treated cells suggests that 5FU
may indeed inhibit the splicing of DHFR pre-mRNA (21–
23). To address whether 5FU incorporation into pre-mRNA
directly affects the splicing, in vitro transcription with various
ratios of 5FUTP:UTP was used to generate 5FU-incorporated
pre-mRNA, which was then subjected to an in vitro splicing
assay. However, the results are inconsistent and somewhat
contradictory. For instance, using 5FU-incorporated human
b-globin pre-mRNA and HeLa nuclear extracts, Doong and
Dolnick detected aberrantly spliced products at relatively
high pH (7.7 or 8.4) (24). In contrast, using the same splicing
system, the Kole group did not detect abnormally spliced
products, even when the b-globin pre-mRNA was fully
substituted with 5FU (25). This discrepancy remains to be
clariﬁed.
Given that the ﬁve spliceosomal snRNPs (U1, U2, U4, U5
and U6) participate in pre-mRNA splicing, it is also possible
that incorporation of 5FU into spliceosomal snRNAs affects
pre-mRNA splicing. Previous work from several groups sug-
gested that 5FU might indeed have inhibitory effect on
snRNP biogenesis and function (25–27). However, it remains
unclear as to how 5FU affects the assembly/function of
snRNPs and whether 5FU is indeed incorporated into
snRNAs in vivo.
Recently, attention has been drawn to the function of
spliceosomal snRNA modiﬁcations. All spliceosomal
snRNAs contain extensive posttranscriptional modiﬁcations,
including 20-O-methylation and pseudouridylation (28,29).
U2 contains the most modiﬁcations. In fact, >10% of the
nucleotides in vertebrate U2 snRNA are modiﬁed (Figure 1).
In particular, all six uridines in or near the U2 branch site
recognition region are converted to pseudouridines after ini-
tial transcription. Using the Xenopus oocyte reconstitution
system, we have demonstrated that modiﬁed nucleotides,
including the pseudouridines in the 50 end region and the
branch site recognition region, are required for U2 function
in splicing (30,31). The importance of the pseudouridines in
the 50 end region was recently conﬁrmed in a HeLa splicing
reconstitution system (32). Importantly, we also demonstrated
that 5FU-containing U2 snRNA is not only non-functional on
its own when injected into Xenopus oocytes but is also a
potent inhibitor that site-speciﬁcally blocks the pseudouridy-
lation of an in vitro transcribed U2 snRNA injected at a later
time (30,31). Thus, we reasoned that 5FU, when incubated
with cells, might incorporate into U2 snRNA (and perhaps
the other spliceosomal snRNAs) at naturally occurring
pseudouridylation sites. The 5FU-incorporated U2 snRNA
might in turn block pseudouridylation of newly synthesized
U2 snRNA in a site-speciﬁc manner (30,31,33), thus inhibit-
ing pre-mRNA splicing.
In the current work, we test the effect of 5FU on U2
snRNA function in HeLa cells. We show that 5FU, even
when supplied at low concentrations to the medium, is in
fact fairly efﬁciently incorporated into HeLa U2 snRNA in
the branch site recognition region, thereby blocking  90%
of pseudouridylation at many important pseudouridylation
sites in this region. Further functional analysis indicates
that hypopseudouridylated U2 snRNA cannot support pre-
mRNA splicing in Xenopus oocytes. Our results identify a
new mechanism by which 5FU affects pre-mRNA splicing.
MATERIALS AND METHODS
Cell culture and total RNA isolation
HeLa cells (ATCC) were cultured at 37 C in Eagle’s Mini-
mum Essential Media (EMEM) (Cambrex) supplemented
with 15% fetal bovine serum (FBS; Sigma). For uracil or
Figure 1. Primary and secondary structure of human and Xenopus U2 snRNA. Pseudouridines (Y) and 20-O-methyl groups (m) are indicated. The gray box
depicts the Sm binding site, and the open box highlights the branch site recognition sequence and its 30-adjacent sequence (collectively referred to as the branch
site recognition region). Arrows indicate the nucleotide differences in Xenopus U2 snRNA.
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indicated in the section Results) of uracil or 5FU was added
freshly to the medium just before culturing. At the end of
incubation (1, 3 or 5 days), cells were collected, and total
RNA was isolated using TRIzol (Invitrogen), according to
manufacturer’s protocol. Puriﬁed total RNA was treated
with  5 U of RQ1 RNase-free DNase I (Promega) at 37 C
for 1 h, extracted with PCA [Tris–HCl–buffered (pH 7.5)
phenol:chloroform:isoamyl alcohol (50:49:1)] and then pre-
cipitated with ethanol.
RT–PCR
Puriﬁed HeLa total RNA (DNA-free) was used for RT–PCR to
determine the levels of mRNA and pre-mRNA. Reverse tran-
scription was carried out with a random DNA primer (9mer)
and M-MLV reverse transcriptase (Invitrogen), according to
manufacturer’s instruction. The cDNA was then used for
PCR reactions in the presence of pairs of forward and reverse
primers, [a-
32P]dATP (PerkinElmer) and Taq polymerase
(Promega). The PCR products were resolved on denaturing
gels and quantiﬁed by a PhosphorImager (Molecular
Dynamics). For nucleolin (GenBank accession no. M60858),
the 50-forward primer speciﬁc for spliced mRNA corre-
sponded to nt 3901–3916 and nt 4587–4596 at the boundary
of exons 3 and 4, respectively; the 50-forward primer speciﬁc
for unspliced pre-mRNA corresponded to nt 4562–4582
located in intron 3; the 30-reverse primer was complementary
to nt 4662–4680 located in exon 4. For GAPDH (GenBank
accession no. J04038), the 50-mRNA-speciﬁc primer corre-
sponded to nt 3996–4012 and nt 4206–4215 at the boundary
of exons 7 and 8, respectively; the 50-pre-mRNA-speciﬁc pri-
mer corresponded to nt 4179–4204 located in intron 7; and the
30-primer was complementary to nt 4391–4414 in exon 8. For
b-globin (GenBank accession no. NG000007), the 50-mRNA-
speciﬁc primer corresponded to nt 71025–71039 and nt
71890–71899 at the boundary of exons 2 and 3, respectively;
the 30-pre-mRNA-speciﬁc primer corresponded to nt 71851–
71870 in intron 2; and the 30-primer was complementary to
nt 71994–72017 in exon 3. For 28S rRNA (as an internal
control), the 50-primer corresponded to nt 1605–1623 and
the 30-primer was complementary to nt 1882–1903 (Genbank
accession no. M11167).
Pseudouridylation quantification
Assays for pseudouridylation and 5FU incorporation were
performed as described previously (34). First, HeLa U2
snRNA was isolated from the puriﬁed total RNA (see
above), using oligonucleotide afﬁnity chromatography.
HeLa total RNA ( 400 mg) was mixed with 100 pmol of
a biotinylated antisense U2 20-O-methyl oligonucleotide
complementary to nt 158–177 of U2 (UmCmCmUmGmG-
mAmGmGmUmAmCmUmGmCmAmAmUmAmCmBBB,
where B stands for biotin-TEG) in 50 ml NET-2-MgCl2 buffer
containing 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 0.05%
(v/v) NP-40 and 2 mM-MgCl2. After denaturing, the sample
was mixed with 20 ml streptavidin beads (Pierce). Following
a 1-h rotation (room temperature), the beads were precipi-
tated and washed with NET-2-MgCl2. U2 was then eluted
with 250 ml of dissociation buffer (10 mM Tris–HCl,
pH 7.5, 0.1% SDS and 0.5 mM EDTA) at 80 C for 15 min,
PCA extracted and ethanol precipitated.
Puriﬁed U2 ( 10–70 ng) was then subjected to RNase H
digestion in the presence of 5 pmol of appropriate 20-O-
methyl RNA–DNA chimera (AmCmAmdCdTdTdGAm-
UmCmUmUmAmGmCmCmAmAm for position 32, Um-
AmdCdAdCdTUmGmAmUmCmUmUmAmGmCmCm for
position 34, AmUmAmdCdTdAdCAmCmUmUmGmAm-
UmCmUmUmAm for position 37, AmGmAmdTdAdCd-
TAmCmAmCmUmUmGmAmUmCmUm for position 39
and GmAmAmdCdAdGdAUmAmCmUmAmCmAmCmU-
mUmGm for position 43) (34). The cleaved 30-half of U2
was gel-puriﬁed, 50-dephosporylated with calf intestinal phos-
phatase (Roche), and subsequently rephosphorylated with T4
polynucleotide kinase (Amersham) and [g-
32P]ATP (34).
The 50-radiolabeled U2 fragment was then treated with
nuclease P1 to completion, dotted on a cellulose TLC PEI
membrane (EM science), and chromatographed in developing
buffer containing isobutyric acid/ammonium/water (50:1:29,
v/v/v) [or isopropanol/HCl/water (70:15:15, v/v/v), as indi-
cated in Results]. The percentage of 5-ﬂuoro-uridylate or
pseudouridylate was quantiﬁed using a PhosphorImager.
Microinjection
Microinjection was carried out essentially as described (30).
Antisense U2 DNA oligonucleotide (50 nl of 3 mg/ml,
complementary to nt 23–46 of human U2) was injected into
Xenopus oocytes to knock out the endogenous U2 RNA. After
an overnight incubation at 18 C, 36.8 nl of 50 ng/ml U2 RNA,
which had been puriﬁed from HeLa cells (see above), were
injected into the U2-depleted oocytes. Following an overnight
incubation, 18 nl of 0.5 · 10
6 c.p.m./ml adenovirus pre-mRNA
(in vitro transcribed with [~ a-
32P]GTP) was injected into the
nuclei. The nuclei were recovered 10 min later, and RNA
was isolated. The total nuclear RNA was then resolved on a
5.5% polyacrylamide-8 M urea gel. Pre-mRNA splicing was
visualized by autoradiography.
To verify whether the 5FU-incorporated adenovirus pre-
mRNA could be spliced, the pre-mRNA (transcribed in vitro
in the presence of 5FUTP and [a-
32P]GTP ) was directly
injected into intact Xenopus oocytes. Splicing was analyzed
by denaturing gel electrophoresis and autoradiography (see
above).
RESULTS
Pre-mRNA splicing is inhibited in HeLa cells
exposed to 5FU
To assess whether 5FU has a general effect on pre-mRNA
splicing, we carried out a quick survey of several randomly
chosen genes using RT–PCR. HeLa cells were exposed to
either 5FU or uracil (as a control) or were not treated (incu-
bated with regular medium) for various amounts of time. As
shown in Figure 2, a low concentration (10 mM) of 5FU, but
not uracil (even when its concentration was higher), was suf-
ﬁcient to induce cell death. After a 5-day exposure to 5FU, a
large fraction of cells died or became sick (Figure 2).
To test whether pre-mRNA splicing was affected in these
cells, we collected cells at several time points and isolated
total RNA for RT–PCR analysis, which allowed us to
552 Nucleic Acids Research, 2007, Vol. 35, No. 2calculate the ratio of levels of corresponding pre-mRNAs and
mRNAs. For many genes tested, we found a relatively higher
ratio of pre-mRNA:mRNA in 5FU-treated cells than in the
control cells, suggesting that the splicing of these pre-
mRNAs was inhibited. Figure 3 shows three typical examples
of such analyses. Here, cells were harvested after incubation
for 5 days. Whereas there was essentially no change in the
GAPDH ratio when cells were exposed to uracil
(panel GAPDH, lane 2) compared with untreated cells (panel
GAPDH, lane 1), a signiﬁcant increase in the GAPDH pre-
mRNA level was observed in cells exposed to 5FU (panel
GAPDH, compare lane 3 with lane 1). In fact, the percentage
of GAPDH pre-mRNA [pre-mRNA/(mRNA+pre-mRNA)]
was >4-fold higher in 5FU-treated cells (lane 3) than in
uracil-treated cells (lane 2) or untreated cells (lane 1). An
even more signiﬁcant change in the nucleolin ratio was
observed when cells were exposed to 5FU; the pre-mRNA
level was greatly increased, whereas the mRNA level was dra-
matically decreased (Figure 3, panel nucleolin, lane 3). In con-
trast, the ratio remained essentially unchanged when cells were
incubated with unsupplemented medium or uracil-containing
medium (compare lane 1 with lane 2). The percentage of
nucleolin pre-mRNA was  11-fold higher in cells exposed
to 5FU (lane 3) compared with cells treated with uracil
(lane 2) or untreated cells (lane 1). Although a rather small dif-
ference in the ratio was detected when b-globin was tested,
there was still a  2-fold increase in the percentage of b-globin
pre-mRNA when cells treated with 5FU (panel b-globin,
lane 3) were compared with the control cells (lanes 1 and 2).
These results suggest that 5FU may indeed have a global effect
on pre-mRNA splicing.
Incorporation of 5FU into pre-mRNA does not affect
splicing in Xenopus oocytes
It is possible that 5FU, when converted into 5FUTP, (a
ribonucleotide analog) in cells, incorporates into pre-
mRNA, thereby affecting splicing. To test this hypothesis,
we incorporated 5FU into adenovirus standard pre-mRNA
splicing substrate via in vitro transcription and then injected
the pre-mRNA into Xenopus oocytes to assess whether it
could be spliced in vivo.
As shown in Figure 4, pre-mRNA containing  20%
5-ﬂuorouridine (derived from T7 in vitro transcription using
a mixture of 5FUTP and UTP, 20:80) was spliced as efﬁcien-
tly as the unsubstituted pre-mRNA (compare lane 5 with lane
4). Remarkably, splicing was not affected even when the
Figure 2. Images of HeLa cells treated with either uracil or 5FU. HeLa cells
were cultured in medium containing either 10 mM uracil (C1, C3 and C5) or
10 mM 5FU (C2, C4 and C6) for 1 day (C1 and C2), 3 days (C3 and C4) or
5 days (C5 and C6). After incubation, the cells were stained with fluorescein
diacetate for live cells (R1) or propidium iodide dye for damaged/dead cells
(R2). Row 3 (R3) shows the phase images.
Figure 3. The levels of pre-mRNA and mRNA in uracil- or 5FU-treated cells.
After a 5-day incubation in the appropriate medium, HeLa cells were
harvested, and pre-mRNA and mRNA levels were assessed, in the same
reaction, by RT–PCR (see Materials and Methods). Total RNA used for
RT–PCR was isolated either from control HeLa cells (regular medium, lane
1), 10 mM uracil-treated HeLa cells (lane 2), or from 10 mM 5FU–treated
HeLa cells (lane 3). The pre-mRNA/mRNA levels of nucleolin, GAPDH and
b-globin are shown; 28S rRNA served as the loading control––under the
conditions used, i.e. low-dose 5FU, rRNA levels were not affected (or no
difference was detected) (43). The percentage of pre-mRNA [pre-mRNA/
(pre-mRNA + mRNA)] for each of the three genes is shown at the bottom of
each panel. The RT–PCR experiments were repeated twice, and the results
were almost identical.
Figure 4. Splicing of pre-mRNA containing 5FU. Uniformly
32P-radiola-
beled standard adenovirus pre-mRNAs containing different levels of 5FU
were separately injected into Xenopus oocytes, and their splicing activity was
monitored by electrophoresis on denaturing gels. The percentage of 5FU in
the pre-mRNA (relative to uridine) is shown above each lane. The migration
positions of pre-mRNA and the spliced products (lariat intron at the top, the
mature spliced mRNA at the bottom) are indicated schematically to the right.
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5FUTP); the levels of the lariat intron and the spliced
mRNA were comparable to those in the control—in which
unmodiﬁed pre-mRNA was injected (lane 6). To verify that
the splicing was accurate, we excised the spliced mRNA
and the lariat intron products and carried out RT–PCR
sequencing and primer-extension analyses. The results indi-
cated accurate usage of the branch site, the 50-splice site
and the 30-splice site (data not shown). Thus, the observed
slow migration of the spliced lariat intermediate (lanes 5
and 6) is likely due to the difference in molecular weight
(i.e. the extra ﬂuorine increases the molecular weight). To
verify that the lack of an effect was not speciﬁc/unique to
the adenovirus splicing substrate, we also tested the splicing
of human b-globin pre-mRNA. Likewise, our results indi-
cated that 5-ﬂuorouridine substitutions did not affect the efﬁ-
ciency and accuracy of b-globin pre-mRNA splicing in
Xenopus oocytes (data not shown).
From these results, we conclude that 5FU incorporation
into pre-mRNA (at least the adenovirus and human b-globin
splicing substrates) does not inﬂuence the splicing of the
pre-mRNA.
5FU incorporates into U2 snRNA at natural
pseudouridylation sites in vivo
Given that 5FU causes a defect in pre-mRNA splicing in
cells, we reasoned that 5FU, after conversion into
5FUTP in the cells, could be incorporated into not only
pre-mRNA/mRNA but also into other types of RNA, includ-
ing spliceosomal snRNAs, possibly at naturally occurring
pseudouridylation sites (such as those in the U2 branch recog-
nition region). According to our previous work, U2 snRNA
containing 5FU at naturally occurring pseudouridylation
sites in the branch site recognition region was by itself not
functional in pre-mRNA splicing; additionally, this 5FU-
containing U2 snRNA was able to inhibit pseudouridine
formation in newly synthesized U2 in a site-speciﬁc manner,
thereby blocking pre-mRNA splicing (30,31).
To analyze 5FU incorporation and its site-speciﬁc
inhibitory effect on pseudouridylation of newly synthesized
U2 in HeLa cells, we used our previously developed method
to examine naturally occurring pseudouridylation sites in the
U2 branch site recognition region (34). HeLa cells were
exposed to 5FU or uracil for 5 days, and endogenous U2
snRNA was isolated via afﬁnity selection using a biotiny-
lated antisense U2 oligonucleotide and was subsequently
analyzed for 5FU incorporation and pseudouridylation
through site-speciﬁc labeling followed by P1 nuclease
digestion and TLC.
We tested all six natural pseudouridine sites (positions 34,
37, 39, 41, 43 and 44) along with one natural uridine site
(U32) in the branch site recognition region. Figure 5 shows
the TLC results of ﬁve of these sites (32, 34, 37, 39 and
43) using a standard cellulose membrane and the developing
solution isobutyric acid:ammonium:water (50:1:29, v/v/v);
this system can separate uridylate, 5F-uridylate and
pseudouridylate. Whereas 5FU incorporation at positions 32
and 34 required a relatively high concentration of 5FU
(1 mM) in the medium (panel Positions 32 and 34), all the
other natural pseudouridine sites were fairly accessible to
5FU even at the low 5FU concentration (10 mM), although
the overall level of 5FU incorporation appeared to be
comparatively low (see panel Positions 37, 39 and 43).
Remarkably, incorporation of 5FU, although at a low level,
effectively blocked the pseudouridylation of newly syn-
thesized U2 at all but one (position 34) naturally occurring
pseudouridylation site in the branch site recognition region
(positions 37, 39 and 41, 43 and 44); a high level of
uridine and a trace of pseudouridine were detected at the
respective sites (see panel Positions 37, 39 and 43, and data
not shown).
5FU incorporation significantly inhibits U2
pseudouridylation at important sites
To assess, in detail, the inhibitory effect of 5FU incorporation
on U2 pseudouridylation in the branch site recognition
region, we further quantiﬁed the level of pseudouridines at
each of the six naturally occurring pseudouridylation sites.
Because the TLC system used in Figure 5 developed
extremely slowly and sometimes yielded distorted migration
patterns, we switched to a cellulose PEI membrane and
changed the developing solution to HCl:water:isopropanol
(15:15:70, v/v/v). Under these conditions, pseudouridylate
(pY) can be well separated from uridylate (pU) and
5F-uridylate (p5FU), although uridylate and 5F-uridylate
Figure 5. Incorporation of 5FU into U2 snRNA at natural pseudouridylation
sites in vivo. U2 snRNA was isolated from HeLa cells that had been treated
with uracil or 5FU (or untreated) for 5 days. 5FU incorporation and
pseudouridylation at natural uridine/pseudouridine sites were subsequently
assayed (see Materials and Methods). Shown are the final TLC (thin layer
chromatography) analyses of the nucleotides at several such sites (positions
32, 34, 37, 39 and 43). The developing solution for TLC was isobutyric
acid:ammonium:water (50:1:29, v/v/v). All but position 32 (a natural uridine
site) are natural pseudouridine sites. In the top panel (panel Positions 32 and
34), cells were treated with 1 mM uracil (lanes 4 and 6) or 1 mM 5FU (lanes 5
and 7) and positions 32 (lanes 4 and 5) and 34 (lanes 6 and 7) were analyzed.
In the other panels (panels Positions 37, 39 and 43), cells were treated with 10
mM uracil (lanes 5) or 10 mM 5FU (lane 6), or were not treated (lane 4). Lanes
1, 2 and 3 are controls in which the
32P-labeled nucleoside 50-mono-
phosphate,
32pU,
32p
5FUo r
32pY, respectively, was analyzed. The migration
positions of pU, p
5FU and pY are indicated on the right.
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lanes 8–10). We note that comigration of uridylate and 5F-
uridylate does not affect quantiﬁcation of pseudouridylation.
As shown in Figure 6, whereas the level of pseudouridylation
at natural modiﬁcation sites was extremely high in U2
snRNA isolated from uracil-treated cells or untreated cells,
pseudouridylation was blocked in U2 snRNA isolated from
5FU-treated cells in a manner dependent on exposure time.
For instance, when cells were exposed to 5FU for 1 day, rela-
tively less inhibition of pseudouridylation was observed in
U2 at all positions tested. When the exposure time was
increased to 3 or 5 days, greater inhibition,  70 or 90%,
was detected, respectively. Interestingly, the only exception
was position 34, the inhibition of which required a signiﬁ-
cantly higher dose of 5FU. This probably reﬂects the fact
that there are two redundant pseudouridylase activities, U92
sno/scaRNP and the human homolog of yeast Pus7p, both
of which can speciﬁcally convert U34 to Y34 (35–37). To
block the two pseudouridylase activities, more 5FU (or longer
exposure) might be required.
Figure 6. Quantification of pseudouridylation of U2 snRNA at natural pseudouridylation sites. Shown are measurements of pseudouridylation at four natural
pseudouridylation sites, positions 34 (panel A), 37 (panel B), 39 (panel C) and 43 (panel D). Experiments were carried out exactly as in Figure 5, except that the
developing solution for TLC was HCl:water:isopropanol (15:15:70, v/v/v), and that cells were analyzed at three different time points of culturing, i.e. 1 day (lanes
2 and 3), 3 days (lanes 4 and 5) and 5 days (lanes 6 and 7). Lane 1 is a control in which U2 snRNA was isolated from cells cultured in regular medium for 3 h
(untreated). In lanes 2, 4 and 6, U2 snRNA isolated from uracil-treated cells was analyzed. In lanes 3, 5 and 7, U2 snRNA isolated from 5FU-treated cells was
analyzed. Lanes 8, 9 and 10 in panel B are controls in which the
32P-labeled nucleoside 50-mono-phosphate,
32pU,
32p5FU or
32pY, respectively, was analyzed.
The positions of pU, p
5FU and pY are indicated to the right. Pseudouridylation at every position was repeated at least twice, and was quantified, as shown at the
bottom of each panel. The percentage of pseudouridylation was calculated using the formula: pY/(pU + p
35U + pY). The white bars, black bars and grey bars
depict the percentage of U2 pseudouridylation in uracil-treated cells, 5FU-treated cells and untreated cells, respectively. The standard deviation (SD) is also
indicated.
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defective in reconstituting pre-mRNA splicing in
Xenopus oocytes
Our previous work showed that U2 snRNA lacking pseudo-
uridines in the branch site recognition region could not func-
tion in pre-mRNA splicing (30). Thus, we tested whether U2
snRNA isolated from 5FU-treated HeLa cells could support
pre-mRNA splicing. Here, since Xenopus U2 and human U2
differ in only a few nucleotides in the 30-half of the
molecule (Figure 1) and they are functionally interchangeable
(31), we directly injected U2 snRNA (isolated from HeLa cell)
into U2-depleted Xenopus oocytes and subsequently assessed
its ability to reconstitute pre-mRNA splicing. U2 snRNA iso-
lated from 5FU-cultured cells functioned poorly (Figure 7,
lanes 6 and 8, 1 and 3 days of 5FU-exposure, respectively)
or failed almost completely (Figure 7, lane 10, 5 days of
5FU-exposure) in restoring pre-mRNA splicing. In contrast,
U2 snRNA isolated from control cells (exposed to uracil or
untreated) fully rescued splicing (Figure 7, lanes 5, 7 and 9).
In summary, our results are consistent with the observation
that pre-mRNA splicing is globally inhibited in HeLa cells
exposed to 5FU, further demonstrating the importance of the
pseudouridines in the branch site recognition region of U2
(and perhaps in other regions of other RNAs as well).
DISCUSSION
Using a quantitative method, we have shown that 5FU,
when included in HeLa cell cultures, is incorporated to a
signiﬁcant extent into U2 snRNA at naturally occurring
pseudouridylation sites. Remarkably, 5FU incorporation
almost completely inhibited the formation of pseudouridines
at sites that normally undergo this modiﬁcation (Figures 5
and 6). More importantly, U2 snRNA isolated from 5FU-
treated cells failed to reconstitute pre-mRNA splicing in
Xenopus oocytes, whereas U2 snRNA extracted from control
cells was fully functional in this regard. These results are con-
sistent with the ﬁnding that 5FU exhibited a global inhibitory
effect on pre-mRNA splicing of several genes we tested
(Figure 3). Thus, our results suggest a new putative mecha-
nism by which 5FU, as an effective anti-cancer drug, counter-
acts the proliferation of cancer cells.
Incorporation of 5FU into spliceosomal snRNAs, but
not pre-mRNAs, blocks pre-mRNA splicing
Whether 5FU incorporation into a pre-mRNA affects splicing
has been a controversial issue. It was reported that a small
fraction of b-globin pre-mRNA containing 5FU (randomly
incorporated into the pre-mRNA by in vitro transcription)
was inaccurately spliced in vitro at pH > 7 (24). However,
using nearly the same system, the Kole group failed to detect
any abnormally spliced products (25). In the current work, we
incorporated 5FU into two different pre-mRNAs and tested
whether they could be accurately spliced in Xenopus oocytes.
Our results indicate that splicing of the substrates (even with
100% 5FU substitution) occurs accurately, efﬁciently, and
comparable to the splicing of unsubstituted pre-mRNAs that
contain no 5FU. Here, the splicing was carried out in Xenopus
oocytes, thus representing an in vivo circumstance. Thus, our
results indicate that the ability of 5FU to inhibit pre-mRNA
splicing is not due to its incorporation into pre-mRNA, at
least for the two genes tested. In contrast, according to our
results, the inhibitory effect of 5FU on splicing is due to its
incorporation into U2 snRNA (and perhaps the other spliceo-
somal snRNAs as well) at naturally occurring pseudouridyla-
tion sites, thereby inhibiting the formation of pseudouridines
that are required for pre-mRNA splicing (Figure 7) (30–32).
Interestingly, however, our results have shown that different
pre-mRNAs are affected differently. This difference in 5FU’s
effect is probably due to intrinsic differences among pre-
mRNAs. For instance, one pre-mRNA might have an intrinsic
enhancer element that helps splicing, whereas another pre-
mRNA might have no such enhancer elements. Consequently,
5FU would show a greater effect on the splicing of the latter
pre-mRNA than that of the former pre-mRNA.
5FU-containing U2 snRNA efficiently blocks the
formation of pseudouridines required for
pre-mRNA splicing
We have previously shown that the injection of 5FU-
containing U2 into oocytes site-speciﬁcally blocks the forma-
tion of pseudouridines in U2 snRNA injected at a later time,
presumably by sequestering or binding irreversibly with pseu-
douridylases (30,31). In the current study, we detected 5FU
incorporation into HeLa U2 snRNA at these important pseu-
douridylation sites and observed a substantial blockade of
pseudouridine formation in newly synthesized U2 snRNA
at the respective sites. Thus, our current results from the
Figure 7. Functional reconstitution of splicing in Xenopus oocytes. U2
snRNA isolated from HeLa cells was injected into U2-depleted Xenopus
oocytes. After a 16-h reconstitution, the oocytes were then injected with
32P-uniformly radiolabeled adenovirus pre-mRNA. The total nuclear RNA
was isolated, 10 min after pre-mRNA injection, and assayed for splicing on a
denaturing gel. Reconstitution was carried out with U2 snRNA isolated from
cells that had been pre-treated with uracil (lanes 5, 7 and 9) or 5FU (lane 6, 8
and 10) for 1 day (lanes 5 and 6), 3 days (lane 7 and 8) or 5 days (lanes 9 and
10). Lanes 3 and 4 are controls where U2-depleted oocytes were reconstituted
for 16 h with no RNA or with the in vitro transcribed U2 snRNA,
respectively. In lane 2,
32P-radiolabeled pre-mRNA was directly injected into
U2 mock–depleted oocytes, and no exogenous U2 was supplemented. Lane 1
represents the uninjected adenovirus pre-mRNA. Lane M is a size marker of
MspI-digested pBR322 DNA. The positions of unspliced pre-mRNA and
spliced products—the lariat intron (top band) and mature mRNA (lower
band)—are indicated schematically.
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from the Xenopus oocyte system. Interestingly, we note that,
depending on individual sites, the extent of inhibition of
pseudouridylation is not always the same. For instance,
whereas pseudouridine formation at positions 37, 39, 41, 43
and 44 was greatly inhibited by 5FU, there was relatively
weak inhibition at position 34. One explanation for this
observation is that perhaps there are multiple or redundant
pseudouridylation activities acting on Y34, and relatively
light incorporation of 5FU at this site may not be sufﬁcient
to block all these activities. Alternatively, the redundant
activities may have different sensitivities to 5FU-containing
U2 snRNA, the pseudouridylation inhibitor. An individual
activity that is less sensitive to the inhibitor may still be
able to catalyze pseudouridine formation at this site in
the presence of the inhibitor. Consistently, Y34 formation
appears to be catalyzed by two redundant activities, the
Pus7p homolog (a protein enzyme) (35) and U92/PugU2-
34/44 (a sno/scaRNP) (36,37). In fact, when PugU2-34/44
is depleted, Y34 formation is not completely irreversibly
blocked. In contrast, Y44 formation, which is also catalyzed
by PugU2-34/44, is completely abolished (36).
We have previously demonstrated that pseudouridines in
the 50 end region and the branch site recognition region are
important for pre-mRNA splicing in Xenopus oocytes
(30,31). Our current results reinforce this conclusion. HeLa
U2 snRNA containing low levels of pseudouridines at the
naturally occurring pseudouridylation sites in the U2 branch
site recognition region (and perhaps in other regions as
well) failed to effectively reconstitute pre-mRNA splicing
in Xenopus oocytes. Although it is still unclear as to how
these pseudouridines contribute to U2 function in splicing,
several lines of evidence suggest that pseudouridines may
enhance RNA–RNA interactions and may even change the
local structure of the interactions that may favor a function-
ally important conﬁguration (38–40). In this regard, the U2
branch site recognition region is involved in base-pairing
interactions with the branch site in the pre-mRNA. A recent
NMR study indicated that at least one of the pseudouridines
in the U2 branch site recognition region can help maintain the
bulge of the branch point adenosine, a conﬁguration believed
to be necessary for nucleophilic attack during the ﬁrst step of
the splicing reaction (41). Based on the recent work of the
Fournier group that several large-subunit rRNA pseudo-
uridines, which are located at the peptidyl transferase center
of the ribosome, synergistically contribute to ribosome func-
tion (42), it is possible that the multiple pseudouridines in the
U2 branch site recognition region contribute to U2 function in
the same synergistic manner. Veriﬁcation of this hypothesis
will require a detailed dissection of the mechanism of action
of these pseudouridines.
Our current work also suggests that 5FU might be incor-
porated into pre-rRNA/rRNAs as well. Although it is still
unclear as to whether incorporation into pre-rRNA will
inhibit its processing, what is clear (or very possible) is that
incorporation of 5FU into the important pseudouridylation
sites within rRNAs (e.g. the pseudouridylation sites in the
peptidyl transferase center, see above) will inhibit pseudo-
uridylation at these sites, thus impairing ribosome function
and protein translation, a scenario supported by strong experi-
mental evidence (42). However, a deﬁnitive answer to this
problem requires further experiments on rRNA/ribosome
biogenesis and function.
Multiple effects of 5FU
It has been widely speculated and in some instances demon-
strated that 5FU affects the metabolism of both DNA and
RNA (2,4). With respect to the effect on RNA metabolism,
efforts have focused primarily on the question of whether
incorporation of 5FU into pre-mRNA or pre-rRNA inﬂuences
the processing efﬁciency and accuracy of these RNAs.
However, despite decades of extensive study, answers to
this question remain somewhat ambiguous. Given that 5FU,
when converted to 5FUTP in the cell, is a ribonucleotide ana-
log, it is equally possible that the nucleotide analog is incor-
porated into the other types of RNA (not just pre-mRNA or
pre-rRNA), some of which may participate in the processing
of pre-mRNA or pre-rRNA, thereby affecting gene expres-
sion. Indeed, our current research provides such an example.
Given that there are a huge number of cellular RNAs, each
exhibiting a unique role in cellular processes, it is not surpris-
ing that 5FU can incorporate into these RNAs and perturb cell
growth in a number of different ways.
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